IQVIA Holdings, Inc. · NYSE:IQV

IQVIA — IQVIA Research Forum 2022

76 slides from IQVIA's conference presentation, October 2022

  1. Slide 1: IQVIA Research Forum 2022

    IQVIA Research Forum 2022 P a t h w a ys a n d P r i o r i t i e s f o r H i g h I m p a c t Health Research October 2022 Copyright © 2019 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.

  2. Slide 2: IQVIA Institute for Human Data Science contributes to advancing human health

    IQVIA Institute for Human Data Science contributes to advancing human health by generating rigorous, evidence-based research PROPRIETARY DATA SOURCES* LIBRARY OF REPORTS EVIDENCE- SUBJECT MATTER EXPERTS BASED RESEARCH CONFERENCES ADVANCED ANALYTICAL SKILLS AND FORUMS THIRD PARTY INFORMATION PEER-REV

  3. Slide 3: Support for academic researchers

    Support for academic researchers How researchers can benefit from IQVIA data IQVIA data assets frequently used in academic research Through collaboration with the IQVIA Institute, Formulary Impact Analyzer: Pharmacy claims with insight into paid, rejected researchers have access to a broad range of

  4. Slide 4: Five key themes

    Five key themes Incorporating Navigating the Elevating the Exploring the complexity the impact of value to Charting the elusive nature and social of applied patients of future of high determinants heterogeneity research in of patient academic impact health on outcomes national health affordability h

  5. Slide 5: Speakers

    Speakers Session 1 Session 2 Kao-Ping Chua, Ph.D., MD Inmaculada Hernandez, PharmD, Ph.D. Assistant Professor, Dept of Pediatrics; Associate Professor, Division of Clinical Assistant Professor Health Management Pharmacy, Skaggs School of Pharmacy and Policy, University of Michigan School and Pharmac

  6. Slide 6: Session 1: Exploring the elusive nature of applied research in national health crises

    Session 1: Exploring the elusive nature of applied research in national health crises 5

  7. Slide 7: Day 1, Session 1: Exploring the Elusive Nature of Applied Research in National Health Crises

    Day 1, Session 1: Exploring the Elusive Nature of Applied Research in National Health Crises Operational Challenges Learning from Research – Data and Methodology Opioid Determining most effective Epidemic Integrating multiple data assets research in national crises COVID-19 Antimicrobial Prioritizin

  8. Slide 8: Challenges of Conducting Timely, High-Quality Health Care Studies During the COVID-19 Pandemic

    Challenges of Conducting Timely, High-Quality Health Care Studies During the COVID-19 Pandemic Kao-Ping Chua, MD, PhD Assistant Professor of Pediatrics Susan B. Meister Child Health Evaluation and Research Center Assistant Professor of Health Management and Policy University of Michigan School of Pu

  9. Slide 9: Two key research challenges during COVID-19

    Two key research challenges during COVID-19 • Data lag: time between the date that data arose and the date that researchers could access them • Publication lag: time between manuscript submission and publication

  10. Slide 10: Many healthcare databases have long lag times

    Many healthcare databases have long lag times • Claims databases: 1-3 years • National surveys (e.g., Medical Expenditure Panel Survey) and discharge databases (e.g., Nationwide Inpatient Sample) – 2 years

  11. Slide 11: Implications of data lag

    Implications of data lag • Many early studies of healthcare during the pandemic were single-center • Tradeoff between timeliness and quality

  12. Slide 12: Implications of data lag

    Implications of data lag • Many early studies of healthcare during the pandemic were single-center • Tradeoff between timeliness and quality • Temptation to publish preliminary data on COVID-19-related changes, rather than wait for more data

  13. Slide 13: Proportion of families with at least one death of an adult from any cause

    Proportion of families with at least one death of an adult from any cause 20- 10- Number per 100,000 families 0- ' + ' ' ' + 9 ' ' 1 1 1 ' 1 1 1 Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan I im 11 im im | 2016 2017 2018 2019 2020 MICHIGAN MEDICINE UNIVERSITY O

  14. Slide 14: Proportion of families with at least one death of an adult from any cause

    Proportion of families with at least one death of an adult from any cause 20- ; 10- Number per 100,000 families 0- ' ¢ 1 ' ' 1 + ' ' 1 © ' ' 1 + ' t+ ' ' 1 1 ' 1 1 Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan L i i 1 1 1 i} ' 2016 ' 2017 ' 2018

  15. Slide 15: Initiatives to increase access to timely data faced implementation challenges

    Initiatives to increase access to timely data faced implementation challenges • COVID-19 Research Database • Consortium of major health data companies deposited data into enclave and allowed free access • Delays associated with gaining access to data and exporting results • IQVIA Human Data Science

  16. Slide 16: Summary

    Summary • Many traditional data sources had too long of a lag to be useful during the pandemic • Real-time data were difficult to access despite stakeholder efforts • Need a nimbler method to get these data in the hands of researchers

  17. Slide 17: Publication lag

    Publication lag • Typical time between submission and publication if manuscript isn’t rejected by the first journal: 4-6 months • Much longer if manuscript is rejected

  18. Slide 18: Implications of publication lag

    Implications of publication lag • Increased use of pre-print servers • Tradeoff between timeliness and quality • Errors resulted in false narratives in the media • Tradeoff between immediate impact and academic advancement • Pre-prints don’t count towards promotion • Many journals do not publish man

  19. Slide 19: Out-of-pocket costs for COVID-19 hospitalization

    Out-of-pocket costs for COVID-19 hospitalization • In 2020, almost all insurers waived cost-sharing for COVID-19 hospitalization, but many started abandoning waivers in early 2021 • Question: how much would patients pay for COVID-19 hospitalizations without cost- sharing waivers? • Analysis of IQVIA

  20. Slide 20: Article usage: May 2021 to September 2022

    Article usage: May 2021 to September 2022 BM) Yale medRyiv ‘THE PREPRINT SERVER FOR HEALTH SCIENCES ‘Show by month Abstract Total 7.047 Picked up by 86 news outlets Blogged by 2 Out-of-Pocket Spending for COVID-19 Hospitalizations in 2020 | Tweeted by 37 See more details © Kao-Ping Chua, @ Rena M. C

  21. Slide 21: Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations

    Views 8,479 | Citations 6 | Altmetric 268 =) Download PDF y) (£) More & CME & MOC (@) Cite This © Permissions XX Original Investigation | Health Policy & October 18, 2021 Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020 Kao-Ping Chua, MD, PhD!:; Rena M. Conti, PhD

  22. Slide 22: Summary

    Summary • Need to align academic incentives with the timely dissemination of data • Academic promotions committees could consider high-impact, non-peer-reviewed products • Journals could adopt a policy that doesn’t penalize pre-prints (despite possibly decreased media attention)

  23. Slide 23: Thank you

    Thank you E-mail: chuak@med.umich.edu @kaopingchua

  24. Slide 24: The Elusive Nature of Applied Research in National Health Crises

    The Elusive Nature of Applied Research in National Health Crises: Antibiotics, Opioids, and COVID-19. Katie J. Suda, PharmD, M.S. Professor of Medicine, Pharmacy & Therapeutics, and Clinical & Translational Sciences University of Pittsburgh School of Medicine Director, Transition to Independence Pro

  25. Slide 25: Disclosures

    Disclosures • I have no actual or potential conflicts of interest in relation to this presentation. • I have received or am currently receiving research funding from AHRQ, CDC, FDA, NIH, and VA HSR&D, VA RR&D, and VA QUERI programs. • Opinions expressed today are those of the presenter and do not re

  26. Slide 26: Every hour of every day

    Every hour of every day….. 3 US persons die 3 US persons die of an infection 5 US persons die of Clostridioides caused by an of an opioid- difficile infection antibiotic-resistant related overdose. (CDI). pathogen. How can national data inform these public health challenges?

  27. Slide 27: CDC: Monitor trends in opioid Rx

    CDC: Monitor trends in opioid Rx. IQVIA Xponent. 2012 2020 High Rx Injury Center. CDC. Available at: https://www.cdc.gov/drugoverdose/rxrate-maps/index.html#print. Accessed October 2, 2022.

  28. Slide 28: Specific specialty: Dental opioids

    Specific specialty: Dental opioids. IQVIA LRx. No change No change Yan CH, et al. Am J Prev Med. 2022;63(1):3-12.

  29. Slide 29: CDC: COVID-19 and antibiotic use

    CDC: COVID-19 and antibiotic use. IQVIA Total Patient Tracker, CDC NHSN AU option. Retail Acute Care CDC. Antibiotic Use in the United States, 2020 Update: Progress and Opportunities. Atlanta, GA: US DHS, CDC; 2021. King LM, et al. Clin Infect Dis. 2021;73:e652-e660. Suda KJ, et al. Antimicrob Agent

  30. Slide 30: Assess Overprescribing

    Assess Overprescribing • 1 in 3 antibiotics prescribed in primary care are unnecessary (NAMCS, Marketscan) • RTI antibiotic: Urgent care > ED > ambulatory care clinics > retail clinics • 1 in 3 dental opioids are overprescribed (Marketscan) • Within health-systems, Black Medicare beneficiaries recei

  31. Slide 31: Equitable distribution: Anti-infectives

    Equitable distribution: Anti-infectives. IQVIA MIDAS. Suda KJ, et al. J Am Pharm Assoc. 2022;62:766.744. Khouja T, et al. J Antimicrob Chemother. 2022;77:1491-1499. Purchasing Rate – Developed Countries Purchasing Rate – Developing Countries Purchases for anti-infectives increased in developed count

  32. Slide 32: Equitable distribution: Opioids

    Equitable distribution: Opioids. IQVIA MIDAS. Gomes T, et al. Pharmacoepi Drug Saf. 2022;31:779-787. Tramadol Developed Codeine countries – Hydrocodone Oxycodone 24% decrease Developing Codeine countries – Tramadol 15% increase

  33. Slide 33: Key messages

    Key messages • Data is critical to address public health crises, target messaging to key groups, and inform interventions locally and nationally. • The ideal data source is at the population-level with ability for granular geographic areas, near real-time, with prescriber, patient, and visit-level c

  34. Slide 34: Thank you

    THANK YOU. ksuda@pitt.edu @SUDAmonas

  35. Slide 35: Buprenorphine for Opioid Use Disorder in the Pandemic: The Dog that Didn't Bark?

    Buprenorphine for Opioid Use Disorder in the Pandemic: The Dog that Didn’t Bark? Brendan Saloner, Ph.D. Johns Hopkins Bloomberg School of Public Health

  36. Slide 36: Detective Gregory and Holmes quote

    Detective Gregory: “Is there any other point to which you would wish to draw my attention?” Holmes: “To the curious incident of the dog in the night-time.” Gregory: “The dog did nothing in the night-time.” Holmes: “That was the curious incident.”

  37. Slide 37: Buprenorphine for Opioid Use Disorder (OUD)

    Buprenorphine for Opioid Use Disorder (OUD) • Most commonly used among the three major medications for opioid use disorder (methadone, buprenorphine, naltrexone) • Highly regulated under federal controlled substance laws (e.g., can only be prescribed by clinicians with a special license) • Optimally

  38. Slide 38: What we expected to happen

    What we expected to happen… • In March 2020, rapid onset of stay at home orders were seen as an imminent threat to people with chronic disease • Pre-pandemic most patients on buprenorphine for OUD were dependent on monthly visits to their prescriber + counseling sessions • Discontinuation of bupreno

  39. Slide 39: But there was a rapid federal response

    …but there was a rapid federal response • Flexibility around telehealth for prescribers, shift to virtual counseling, decreased required urine testing

  40. Slide 40: Aggregate Analysis of Buprenorphine During the Early Pandemic Months

    Aggregate Analysis of Buprenorphine During the Early Pandemic Months • Aggregate analysis of trends using Symphony Health data from May 1, 2019 to June 28, 2020 • Comparison of buprenorphine fill quantities versus all filled prescriptions • Test for differences in trends pre- versus post-pandemic

  41. Slide 41: Assessment of filled buprenorphine prescriptions during COVID-19

    Nguyen, T. D., Gupta, S., Ziedan, E., Simon, K. I., Alexander, G. C., Saloner, B., & Stein, B. D. (2021). Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic. JAMA internal medicine, 181(4), 562-565.

  42. Slide 42: Was the Stability in Buprenorphine Fills Experienced by All Groups?

    Was the Stability in Buprenorphine Fills Experienced by All Groups? • Follow-up analysis using fill-level data from IQVIA provided through Human Data Science Research Collaborative • We estimate multilevel models (patient, prescriber, ZIP, region) for risk of discontinuation in each of two time peri

  43. Slide 43: Discontinuation rate decreased from 2019 to 2020

    Discontinuation rate decreased from 2019 to 2020, and predictors were very similar • 15.7% discontinued in 2019 versus 14.0% in 2020 • Strongest predictors of discontinuation in both time periods: younger age (versus older), lower volume prescribers and PA/NP • New England states had notably lower d

  44. Slide 44: Percent of Patients Stopping Buprenorphine in May-August

    Percent of Patients Stopping Buprenorphine in May-August 10% 20% 30% 40% 50% 60% 70% 0% 0.01 0.03 0.05 0.07 0.09 0.11 0.13 0.15 0.17 0.19 0.21 0.23 0.25 0.27 0.29 0.31 0.33 0.35 0.37 0.39 0.41 0.43 2019 0.45 0.47 0.49 0.51 0.53 2020 0.55 Prescriber Percentile 0.57 0.59 0.61 0.63 0.65 0.67 0.69 0.71

  45. Slide 45: Percent of Patients Stopping Buprenorphine in May-August

    Percent of Patients Stopping Buprenorphine in May-August 10% 20% 30% 40% 50% 60% 70% 0% 0.01 0.03 0.05 0.07 0.09 0.11 0.13 0.15 0.17 0.19 0.21 0.23 2019 0.25 0.27 0.29 0.31 2020 0.33 % of patients who discontinue 0.35 0.37 0.39 0.41 0.43 2019 0.45 0.47 0.49 0.51 0.53 2020 0.55 Prescriber Percentile

  46. Slide 46: Was Buprenorphine Use the Dog that Didn't Bark in the Pandemic?

    Was Buprenorphine Use the Dog that Didn’t Bark in the Pandemic? • The remarkable continuity of treatment for buprenorphine patients defied expectations that treatment would fall of rapidly • Continuity likely due to the success of federal provisions • A policy paradox: Stability during a time of str

  47. Slide 47: Some important caveats

    Some important caveats • Stability for new patients may not be the full story – we still need to understand what happened to people who were not yet in the system • Overall, access to buprenorphine is not meeting the urgency of the national overdose crisis

  48. Slide 48: Thank you!

    Thank you! References: Nguyen TD, Gupta S, Ziedan E, Simon KI, Alexander GC, Saloner B, Stein BD. Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic. JAMA internal medicine. 2021 Apr 1;181(4):562-5. Saloner B, Chang HY, Alexander GC,

  49. Slide 49: Panel Discussion

    Panel Discussion Presenters Kao-Ping Chua Katie Suda Brendan Saloner Assistant Professor Professor of Medicine Associate Professor University of Michigan School of University of Pittsburgh Department Department of Health Policy and Public Health of Medicine Management, Johns Hopkins Bloomberg School

  50. Slide 50: Q&A

    Q&A Post your questions and comments in the Q&A box. 49

  51. Slide 51: Session 2: Incorporating the impact of social determinants on outcomes in healthcare research

    Session 2: Incorporating the impact of social determinants on outcomes in healthcare research 50

  52. Slide 52: IQVIA Research Forum agenda

    IQVIA Research Forum agenda Incorporating Navigating the Elevating the Exploring the complexity the impact of value to Charting the elusive nature and social of applied patients of future of high determinants heterogeneity research in of patient academic impact health on outcomes national health aff

  53. Slide 53: Incorporating the impact of social determinants on outcomes in healthcare research

    Incorporating the impact of social determinants on outcomes in healthcare research Overview The social determinants of health – income, education, housing, work, food, and other social and environmental conditions– is of growing importance in healthcare research when understanding the impact of non-

  54. Slide 54: Integrating non-traditional data sources to study the impact of social determinants on health outcomes

    Integrating non-traditional data sources to study the impact of social determinants on health outcomes Susan dosReis, PhD Professor & Vice Chair for Research University of Maryland School of Pharmacy October 10, 2022

  55. Slide 55: Impact of Diverse Social Determinants

    Impact of Diverse Social Determinants Health outcomes are impacted by multi-stakeholder interactions Healthcare Policies (consumers, providers, policy Medication Quality Benchmarks Care Coordination makers) in diverse settings Healthcare Access Crime Housing Internet Access Area Deprivation Index Me

  56. Slide 56: Measures of Social Determinants

    Measures of Social Determinants Area Deprivation Index Indicators of Socioeconomic Disadvantage Domain Area Deprivation Measure Median family income Income disparity Percent of families below the poverty level Percent of the population <150% poverty threshold Poverty Percent single parent households

  57. Slide 57: Social Determinants and Policy Effects in Vulnerable or Underserved Populations

    Social Determinants and Policy Effects in Vulnerable or Underserved Populations Optimized Hot Spot Analysis & Youth in Zipcode Tabulation Area (ZCTA) Cold Percent Change in Psychotropic and Antipsychotic Prevalence by Hot, Cold, and Neutral Spots of Deprivation Hot Cold Neutral Hot Psychotropic Over

  58. Slide 58: Practical Considerations

    Practical Considerations • Need for granular data at each level to better assess the impact of social determinants • Link social determinants across the multiple levels • Define endpoints across the spectrum of social determinants

  59. Slide 59: Practical considerations for the study of social determinants of health in large administrative data

    Practical considerations for the study of social determinants of health in large administrative data October 10, 2022 Inmaculada (Inma) Hernandez, PharmD, PhD, FACC, FAHA Associate Professor of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences UC, San Diego inhernandez@health.u

  60. Slide 60: Social determinants of health

    Social Our Comparative Effectiveness Research on Acknowledgements & Determinants of Health AnticoagulantsDisclosures Social determinants of health (SDoH) • The conditions in which people are born, grow, live, work and age • Critical to capture individual-level AND neighborhood-level factors in SDoH

  61. Slide 61: Practical challenges (I)

    Ourchallenges Comparative Practical Practical (I) Effectiveness Acknowledgements challenges (I) Research & on AnticoagulantsDisclosures Related to data sources • Comprehensive datasets capture highly specific population segments • Underrepresentation of individuals without insurance, with intermitte

  62. Slide 62: Practical challenges (II)

    Ourchallenges Comparative Practical Practical (II) Effectiveness Acknowledgements challenges (II) Research & on AnticoagulantsDisclosures Neighborhood-level factors • Low granularity of patient-level address information • Available geographic units are often: • Large and heterogeneous • Not linkable

  63. Slide 63: Recommendations

    Our Comparative Effectiveness Research Acknowledgements Recommendations Recommendations & on AnticoagulantsDisclosures ✓Need to re-envision data security standards to enable SDoH research while maintaining highest-levels of data protection ✓Need to work on the development of nationwide data reposito

  64. Slide 64: Structural Racism and Health Equity Research: Evidence Needed to Address Disparities in Access to Medicines

    Structural Racism and Health Equity Research: Evidence Needed to Address Disparities in Access to Medicines Dima M Qato, MPH, PharmD, PhD Hygeia Centennial Chair and Associate Professor of Pharmacy Senior Fellow, Schaeffer Center for Health Policy and Economics University of Southern California @dim

  65. Slide 65: Structural racism is a fundamental cause of SDoH and health disparities

    Structural racism is a fundamental cause of SDoH and health disparities Braveman P, Gottlieb L. Public Health Reports.

  66. Slide 66: Structural Racism as a fundamental cause of disparities in access to medicines

    Structural Racism as a fundamental cause of disparities in access to and use of medicines in the U.S. Structural Racism (Federal, state, local health policies and practices) Racial/Ethnic residential Geographic Variation in Pharmacy Systems and Affordability of Segregation Services Prescription Med

  67. Slide 67: Challenges to incorporate measures of structural racism in health equity research

    Challenges to incorporate measures of structural racism in health equity research o Lack of clarity on definitions/measures of structural racism in the context of health policy → access to medicines • Residential racial/ethnic segregation (neighborhood-level) • How about structural racism within Med

  68. Slide 68: Pharmacy Deserts and Closures in Chicago

    Pharmacy Pharmacy Deserts and Closures in Chicago Worsened in Access Segregated Black and Latinx Neighborhoods Since 2015

  69. Slide 69: Implications of failing to incorporate structural racism in health equity research

    What are the implications of failing to incorporate structural racism in health equity research? o Perpetuate structural racism within health systems and policies that contribute to persistent, worsening Inequitable access to essential medicines in Black and Hispanic populations in the U.S. 1. We kn

  70. Slide 70: Opportunities for research to inform evidence-based policies

    Opportunities for research to inform evidence-based policies that reduce, not worsen, inequitable access to medicines o Develop and integrate measures in available data sources that have the potential to change existing policies AND promote racial equity • Promote accountability→ Who is responsible

  71. Slide 71: Panel Discussion

    Panel Discussion Presenters Susan dosReis Inmaculada Hernandez Dima Qato Professor Associate Professor Associate Professor University of Maryland School of UC San Diego Skaggs School of University of Southern California Pharmacy Pharmacy and Pharmaceutical School of Pharmacy Sciences 70

  72. Slide 72: Q&A

    Q&A Post your questions and comments in the Q&A box 71

  73. Slide 73: IQVIA Research Forum agenda

    IQVIA Research Forum agenda Incorporating Navigating the Elevating the Exploring the complexity the impact of value to Charting the elusive nature and social of applied patients of future of high determinants heterogeneity research in of patient academic impact health on outcomes national health aff

  74. Slide 74: Thank you

    IQVIA INSTITUTE FOR HUMAN DATA SCIENCE Thank you

  75. Slide 75: Download featured Institute content

    Download featured Institute content www.IQVIAInstitute.org Find us on social media Twitter: @IQVIA_Institute LinkedIn: #IQVIAInstitute 74

  76. Slide 76: Thank you

    Thank you Global Trends in R&D: Overview through 2020. Report by the IQVIA Institute for Human Data Science.

IQVIA Holdings — IQVIA Research Forum 2022 on 6ix